![]() |
Name |
Peniphenone
|
Molecular Formula | C14H10O6 | |
IUPAC Name* |
2-(2,6-dihydroxybenzoyl)-3-hydroxybenzoic acid
|
|
SMILES |
C1=CC(=C(C(=C1)O)C(=O)C2=C(C=CC=C2O)O)C(=O)O
|
|
InChI |
InChI=1S/C14H10O6/c15-8-4-1-3-7(14(19)20)11(8)13(18)12-9(16)5-2-6-10(12)17/h1-6,15-17H,(H,19,20)
|
|
InChIKey |
NIEOVCLPEHLZFT-UHFFFAOYSA-N
|
|
Synonyms |
Peniphenone
|
|
CAS | NA | |
PubChem CID | 139585066 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 274.22 | ALogp: | 2.3 |
HBD: | 4 | HBA: | 6 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 115.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 20 | QED Weighted: | 0.638 |
Caco-2 Permeability: | -5.623 | MDCK Permeability: | 0.00000709 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.232 | 20% Bioavailability (F20%): | 0.903 |
30% Bioavailability (F30%): | 0.998 |
Blood-Brain-Barrier Penetration (BBB): | 0.164 | Plasma Protein Binding (PPB): | 99.41% |
Volume Distribution (VD): | 0.348 | Fu: | 1.12% |
CYP1A2-inhibitor: | 0.483 | CYP1A2-substrate: | 0.068 |
CYP2C19-inhibitor: | 0.043 | CYP2C19-substrate: | 0.041 |
CYP2C9-inhibitor: | 0.575 | CYP2C9-substrate: | 0.131 |
CYP2D6-inhibitor: | 0.402 | CYP2D6-substrate: | 0.127 |
CYP3A4-inhibitor: | 0.141 | CYP3A4-substrate: | 0.078 |
Clearance (CL): | 3.946 | Half-life (T1/2): | 0.858 |
hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.172 |
Drug-inuced Liver Injury (DILI): | 0.986 | AMES Toxicity: | 0.904 |
Rat Oral Acute Toxicity: | 0.025 | Maximum Recommended Daily Dose: | 0.005 |
Skin Sensitization: | 0.725 | Carcinogencity: | 0.648 |
Eye Corrosion: | 0.005 | Eye Irritation: | 0.966 |
Respiratory Toxicity: | 0.221 |